Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEGEAN: Neoadjuvant/adjuvant durvalumab in resectable stage II–III NSCLC
2018-002997-29Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab + chemotherapy with Placebo + chemotherapy (2 arms). Primary endpoint: Major Pathological Response (mPR) in full analysis set. Started Nov 2018; status: active.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-002997-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002997-29.